Celsion Corp


Cantor Maintains Buy On Celsion Following Update On ThermoDox HEAT Study

Cantor’s analyst Daniel Brims weighed in on Celsion Corporation (NASDAQ:CLSN), after the company reported updated results from its retrospective analysis of the Company’s 701-patient HEAT Study of ThermoDox, …

H.C. Wainwright Reiterates Buy On Celsion Following Release Of 3Q14 Results

In a research report published yesterday, H.C.

Celsion Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report published August 8th, H.C.

HC Wainwright Reiterates Buy On Celsion Following The Company’s Latest Announcements

Celsion Corp. (CLSN) announced interim data from the ongoing Phase 2 DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer (RCWBC), where …

H.C. Wainwright Reiterates Buy On Celsion Following Meeting With Management

In a research report issued today, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts